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Abstract
Background: Gene therapy is a promising therapeutic approach for cancer. Targeted expression of desired
therapeutic proteins within the tumor is the best approach to reduce toxicity and improve survival. This study is to
establish a more effective and less toxic gene therapy of cancer.
Methods: Combined gene therapy strategy with recombinant adenovirus expressing horseradish peroxidase (HRP)
mediated by human telomerase reverse transcriptase (hTERT) promoter (AdhTERTHRP) and murine interleukin-12
(mIL-12) under the control of Cytomegalovirus (CMV) promoter (AdCMVmIL-12) was developed and evaluated
against Lewis lung carcinoma (LLC) both in vivo and in vitro. The mechanism of action and systemic toxicities were
also investigated.
Results: The combination of AdhTERTHRP/indole-3-acetic acid (IAA) treatment and AdCMVmIL-12 resulted in
significant tumor growth inhibition and survival improvement compared with AdhTERTHRP/IAA alone (tumor
volume, 427.4 ± 48.7 mm
3 vs 581.9 ± 46.9 mm
3, p = 0.005 on day 15; median overall survival (OS), 51 d vs 33 d) or
AdCMVmIL-12 alone (tumor volume, 362.2 ± 33.8 mm
3 vs 494.4 ± 70.2 mm
3, p = 0.046 on day 12; median OS, 51 d
vs 36 d). The combination treatment stimulated more CD4
+ and CD8
+ T lymphocyte infiltration in tumors,
compared with either AdCMVmIL-12 alone (1.3-fold increase for CD4
+ T cells and 1.2-fold increase for CD8
+ T cells,
P < 0.01) or AdhTERTHRP alone (2.1-fold increase for CD4
+ T cells and 2.2-fold increase for CD8
+ T cells, P < 0.01).
The apoptotic cells in combination group were significantly increased in comparison with AdCMVmIL-12 alone
group (2.8-fold increase, P < 0.01) or AdhTERTHRP alone group (1.6-fold increase, P < 0.01). No significant
systematic toxicities were observed.
Conclusions: Combination gene therapy with AdhTERTHRP/IAA and AdCMVmIL-12 could significantly inhibit tumor
growth and improve host survival in LLC model, without significant systemic adverse effects.
Background
Over the last years, gene therapy has emerged as a pro-
mising strategy for cancer treatment [1]. However, some
limitations are associated with its clinical application, the
reduced specificity to deliver functional therapeutic genes
into tumor cells being the major one [2]. Therefore,
research in gene therapy has been focused on the devel-
opment of targeting strategies.
Tissue- or cell-specific promoters represent one of the
main methods of gene targeting. The human telomerase
reverse transcriptase (hTERT) promoter has been widely
used in gene therapy for targeting cancer cells, which is
highly active in human cancer cells but not in normal dif-
ferentiated human cells [3-6].Therefore, it fulfilled the
characteristic of tumor origins with marked heterogeneity.
Meanwhile, it was demonstrated that hTERT promoter
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cancer cell lines, but not in normal human cells in adeno-
virus mediated transgene experiments [7,8]. Furthermore,
Gu et al[9] showed that hTERT promoter could efficiently
use mouse transcription machinery despite the apparent
distinct regulatory mechanisms, and that hTERT promoter
was highly active in murine tumor cells, but quiescent in
normal murine cells and tissues. These findings indicated
that hTERT promoter should be useful for targeting the
pharmaceutical effects of a therapeutic gene to cancer
cells.
Gene directed enzyme/prodrug therapy (GDEPT) or
suicide gene therapy using viral vectors is an attractive
alternative approach to cancer therapy, with the potential
to give therapeutic ratios superior to standard chemo-
and radiotherapy [10]. The horseradish peroxidase
(HRP)/indole-3-acetic acid (IAA) system is a novel
GDEPT system, which has shown great efficacy in killing
tumor cells. In this setting, a viral vector expressing a
therapeutic enzyme (HRP) is delivered to the tumor cells.
The nontoxic prodrug (IAA) is administered systemically
by intravenous injection or locally by intraperitoneal or
intratumoral injection to maximize its concentration
within the tumor, and converted into cytotoxic metabo-
lites by HRP. It was demonstrated that HRP/IAA system
was more cytotoxic to tumors than the well-known HSV-
tk/GCV system [11,12]. Furthermore, HRP is normally
absent in mammalian cells and IAA is a poor substrate
for mammalian peroxidases, thus systemic toxicity is
avoided [13].
To optimize the therapeutic efficacy of suicide gene
therapy, it is important to explore new strategies of
combined therapy, which employ targeted suicide gene
in combination with immunotherapy that cooperatively
enhance the antitumor effects while mitigating side
effects. Immunotherapy uses the transfer of genes of
various cytokines and co-stimulatory molecule into
tumor cells to stimulate an antitumoral immune
response in experimental animals [14]. Interleukin-12
(IL-12) is a heterodimetic cytokine, composed of
35 KDa (p35) and 40 KDa (p40) subunits, which bind to
receptors present on NK and T cells [15]. IL-12 plays
multiple roles in the immune system, such as augment-
ing the proliferation and cytotoxic activity of T cells and
NK cells and initiating Th1-type immune responses by
activation of CD4
+ and CD8
+ cells [16].
In the present study, we investigated a combined tar-
get suicide gene therapy and immunomodulating gene
therapy approach for Lewis lung carcinoma (LLC),
based on the delivery of HRP/IAA and murine IL-12 by
the same adenovirus vector. These studies were per-
formed both in vitro, by measuring cell viability, and
in vivo, by determining the tumor size and animal survi-
val, assessing both tumoral histology and infiltration of
T-lymphocytes, and evaluating toxic studies. The data
showed that combination gene therapy increased the
therapeutic efficiency in the murine LLC model used in
this study.
Materials and methods
Cell culture and animals
LLC and A549 cell lines were obtained from the Cell
Bank of the Chinese Academy of Science (Shanghai,
China) and maintained in 5% CO2 at 37°C in Dulbecco’s
minimum essential medium (DMEM) containing 10%
fetal bovine serum (FBS), 100 U/ml penicillin and
100 mg/ml streptomycin. All culture reagents were pur-
chased from Hyclone (Logan, UT, USA) or Invitrogen
(Gaithersburg, MD, USA). Being syngenic with LLC,
male C57BL/6 mice (6-week old) obtained from Shang-
hai SLAC Laboratory Animal Co. Ltd (Shanghai, China)
were housed in specific pathogen-free condition at the
Animal Experimental Center of Wuhan University. The
facilities and the protocol were consistent with the regu-
lations on animal use for biomedical experiments issued
by the Ministry of Science and Technology of China,
and approved by the Animal Care Committee of Wuhan
University.
Recombinant adenoviruses
The plasmid phTERTHRP constructed in our lab as
described [17-19] was digested with MluI and BamHI,
and subcloned into the same site of pAdTrack-C (which
was modified by inserting MluI and BamHI clone sites
based on pAdTrack) to generate pAdhTERTHRP. The
murine IL-12 obtained from pUMVC3-mIL12 (Aldevron
Inc., Fargo, USA) was subcloned into pAdTrackCMV to
generate pAdCMVmIL-12 by digesting with SalI and
NotI. The shuttle vector pAdTrack and Escherichia coli
AdEasy-1 were kindly provided by Dr. JG Wu (State
Key Laboratory of Virology, College of Life Sciences at
Wuhan University, China). For recombinant prAdh-
TERTHRP and prAdCMVIL-12, homologous recombi-
nation was performed as described previously [20].
Recombinant adenoviruses were packaged by GeneChem
Co., Ltd (Shanghai, China). Briefly, recombinant plas-
mids were transfected into 293 cells to obtain adeno-
virus prestocks. Virus was purified by double cesium
chloride gradient ultracentrifugation. Viral titer was
determined by plaque assay and expressed as plaque-
forming units (pfu). Purified virus aliquots were stored
at -80°C.
In vitro studies
For adenoviral gene transduction efficiency in vitro,
A549 and LLC cells were infected with AdCMV(-) at
multiplicity of infection (MOI) of 1, 10, 100 and 1,000.
After incubation for 48 hours, the cells were analyzed
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USA) for green fluorescent protein (GFP) expression.
Subsequently, LLC cells were transduced with AdCMV
(-), AdCMVmIL-12 and AdhTERTHRP alone or in
combination at appropriate MOI. Cell proteins were
harvested and the expression of HRP was detected by
western blot. Culture supernatants were collected for
determination of IL-12 concentration by a sandwich
enzyme-linked immunosorbant assay (ELISA).
For cytotoxicity of HRP/IAA system, LLC cells (2 × 10
3/
well) were plated in 96-well plates and allowed to adhere
overnight. The cells were transduced as described above
and incubated for 16 hours. Then fresh media containing
IAA (Sigma, MO, USA) at a concentration of 0-5 mM were
exchanged every 48 hours. Cell viability was determined by
MTT assay (Invitrogen, CA, USA) 120 hours later and the
optical density value was measured by a microplate reader
(Turner BioSystems, CA, USA).
In vivo studies
At o t a lo f5 × 1 0
6 LLC cells were inoculated subcuta-
neously in the right flank of C57BL/6 mice. After
14 days, the tumor was isolated, prepared to cell suspen-
sion and inoculated into new mice. When the tumors
reached 5-6 mm in diameter (Day 10), the mice were
randomized to 4 groups (n = 13 each): group I, AdCMV
(-) (1 × 10
9 pfu); group II, single-agent AdhTERTHRP
(5 × 10
8 pfu); group III, single-agent AdCMVmIL-12
(5 × 10
8 pfu); group IV, combination AdCMVmIL-12
and AdhTERTHRP (5 × 10
8 pfu + 5 × 10
8 pfu). The
adenoviruses were diluted in 30 μl phosphate buffered
saline (PBS). 48 hours after virus injection (Day 12),
3 mice of each group were sacrificed for examining
HRP and IL-12 expression in tumor tissues. Meanwhile,
IAA (50 mg/kg daily) was administered to the rest mice
by intraperitoneal injection for 7 days from Day 12 to
18. Five mice from each group were sacrificed for evalu-
ating the effects of various treatments on Day 19. In
addition, survival studies were set up with different
treatment groups of animals (n = 5) in an identical
manner. Tumor size was measured using caliper every
3 days and the volume was calculated using the follow-
ing formula: (L × W
2)/2, where L equals length and W
equals width. Animals with very high tumor volume
(exceeded 3500 mm
3) were sacrificed for ethical reasons
and this was recorded as the date of death for survival
studies. The general scheme of in vivo experiment was
outlined in Figure 1.
Western blot analysis
H R Pe x p r e s s i o ni nL L Cc e l l sa n ds u b c u t a n e o u st u m o r s
infected with AdCMV(-), AdhTERTHRP and AdCMVmIL-
12 alone or in combination was determined by Western
blot. Transduced cells and tumor tissues were lysed in
2× sample buffer (100 mM Tris-HCl pH6.8, 200 mM DTT,
4% SDS, 20% glycerol and 0.2% bromoplenol blue) and
separated by 10% SDS-PAGE. Proteins were transferred to
PVDF membranes (Millipore, MA, USA) and then
immersed in a blocking solution containing 5% non-fat
milk and 0.1% tween-20 for 1 hour. Afterwards, the mem-
branes were incubated with mouse anti-HRP (dilution,
1:500) or mouse anti-b-actin (dilution, 1:1000) for 2 hours
and with goat anti-mouse secondary antibody (dilution,
1:10000) for 1 hour at room temperature. All the antibodies
were purchased from Santa Cruz Biotechnology (Santa
Cruz, USA). Enhanced chemiluminescence (Beyotime,
Shanghai, China) was used to visualize the immunoreactive
bands.
ELISA
Culture supernatants of transduced LLC cells and tumor
tissue lysates of treated mice were collected. The IL-12
concentration was determined using a sandwich ELISA
(R&D systems, CA, USA) according to the manufacturer’s
instructions.
Immunohistochemical analysis and apoptosis assay
Tumor tissues were formalin fixed and 4 μm sections were
stained with hematoxylin and eosin for routine histological
analysis. For immunohistochemical analysis, acetone fixed
fresh-frozen sections were stained for infiltration T lym-
phocytes (CD4
+ and CD8
+) with specific antibodies (BD
PharMingen, CA, USA) following standard method as
described [21]. For apoptosis assay, formalin fixed sections
were analyzed for DNA fragmentation by terminal deoxy-
necleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) assay (Roch, NJ, USA) according to the manufac-
turer’s instructions. Cell proliferation was also determined
using anti-Ki-67 antibody (Santa Cruz Biotechnology,
Santa Cruz, USA). Positive staining was scored by light
microscopy. After initial scanning under × 100 magnifica-
tion, positively stained cells in ten fields under × 400
(0.15 mm
2) magnification were counted and the mean
number/high power field (HPF ± SEM) was determined.
In vivo toxicity studies
Sera were collected from the treated animals to measure
the biochemistry markers including alanine transami-
nase (ALT), aspartate aminotransferase (AST), blood
urea nitrogen (BUN) and creatine (Cr) using commercial
kits (Sigma, MO, USA). For histological examination,
some tissues were harvested, fixed with formalin and
stained with hematoxylin and eosin. 3 mice without any
treatment were used as normal control.
Statistical analysis
The significance of differences between experimental
groups was calculated using Student’s t-test or one-way
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were compared using the log-rank test. In all cases,
P values less than 0.05 were considered statistically sig-
nificant. Analysis was performed with the GraphPad
Prism 5 (version 5.01, GraphPad software, Inc.).
Results
Gene transfer efficiency in LLC cells with Adenoviruses
LLC cells were relatively resistant to infection by
AdCMV(-) compared with A549 cells. Only a few LLC
cells were infected at MOI of 10. When the MOI
increased to 100 and 1000, the percentages of trans-
duced cells were up to 10-15% and 40-45% (Figure 2A).
Thus the MOI of 1000 was chosen for the subsequent
studies.
HRP and IL-12 expression in vitro
LLC cells transduced with AdCMV(-), AdhTERTHRP
and AdCMVmIL-12 alone or in combination were har-
vested and determined by western blot for the expression
of HRP. Results showed that the HRP expression was
observed in AdhTERTHRP alone group and combination
g r o u pw h e r e a sn o ti nA d C M V ( - )o rA d C M V m I L - 1 2
alone groups (Figure 2B). The expression levels of IL-12
in culture supernatant were measured by ELISA assay.
LLC cells in AdCMVmIL-12 alone and in combination
groups resulted in secretiono fu pt o5 . 8n g / m l ,b u tn o
IL-12 expression was detected in supernatants from
AdCMV(-) or AdhTERTHRP alone groups (Figure 2C).
Cytotoxicity of the HRP/IAA system in vitro
To validate the biological activity of exogenous HRP,
transduced LLC cells were treated with IAA at indicated
concentrations in Figure 2D. The results were shown as
the percentage of cell viability with respect to control cells
without IAA treatment. LLC cells in AdhTERTHRP alone
group and combination group exhibited a dose-dependent
manner of cytotoxicity, and both the IC50 of IAA was
about 3.0 mM. The results indicated that HRP/IAA system
had efficient cytotoxic effects on LLC cells. However, high
concentration of IAA (more than 5 mM) showed mild
toxicity on HRP-negative cells.
In vivo antitumor effect of gene therapy
The LLC mouse model was used to assess the in vivo anti-
tumor activity of AdhTERTHRP and AdCMVmIL-12 as
single agent or in combination. First of all, the expression
of HRP and IL-12 in tumors was determined and similar
results were found as in vitro (Figure 3A and 3B). For
tumor growth, the data clearly showed remarkable inhibi-
tion of combining AdCMVmIL-12 and AdhTERTHRP
treatment in comparison with AdCMV(-), AdCMVmIL-12
and AdhTERTHRP alone (Figure 3C). AdhTERTHRP
treatment (group II) significantly suppressed tumor growth
through day 6 to 24 compared with AdCMV(-) treatment
(group I) (groups II vs I, p = 0.024). AdCMVmIL-12 treat-
ment (group III) was associated with more potent antitu-
mor effects (groups III vs II, p > 0.05; groups III vs I, p =
0.047 on day 9 to 24). Combination treatment with
AdhTERTHRP and AdCMVmIL-12 (group IV) was asso-
ciated with the most marked suppression of tumor growth
(groups IV vs III, p = 0.046 on day 12 to 24; groups IV vs
II, p = 0.005 on day 15 to 24; groups IV vs I, p = 0.029
on day 6 to 24). These results indicated that both
AdhTERTHRP alone and AdCMVmIL-12 alone sup-
pressed tumor growth, and the combination showed syner-
gistic antitumor effects. As a consequence, five animals
from each group were monitored and survival curves were
established (Figure 3D). Mice treated with the combination
regimen had a significant survival advantage with the med-
ian survival increase to 51 versus 36 days for AdCMVmIL-
12 alone-treated mice, 33 days for AdhTERTHRP alone-
treated mice and 24 days for AdCMV(-) control treated
mice (Figure 3B). Statistical comparison (log-rank test)
showed a significant difference (P = 0.0001) and a signifi-
cant trend between treatment groups (P = 0.0003).
T lymphocyte infiltration in tumors
The antitumoral activity of immuno-gene therapy strate-
gies involved the activation of the immune system
Figure 1 General outline of the in vivo experimentation with mouse model of LLC.
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different treatments on immune cell infiltration in local
tumors, immunohistochemistry was performed against
CD4
+ and CD8
+ T cells (Figure 4; Table 1). The results
revealed that the combination therapy (AdhTERTHRP +
AdCMVmIL-12) led to extensive tumor infiltration by
CD4
+ T cells (P < 0.0001, 9.4-fold) and CD8
+ T cells (P <
0.0001, 8.6-fold) compared with AdCMV(-) group. The
infiltration of CD4
+ and CD8
+ T cells in combination
group was also substantially greater than that observed in
tumors given either AdCMVmIL-12 (P = 0.002, 1.3-fold
for CD4
+ T cells; P = 0.001, 1.2-fold for CD8
+ T cells) or
AdhTERTHRP (P < 0.0001, 2.1-fold for CD4
+ T cells; P <
0.0001, 2.2-fold for CD8
+ T cells) alone.
Apoptosis and proliferation in tumors
To examine potential mechanism of treatment-related
antitumor effects, apoptosis and proliferation were assessed
in tumors from different treatment groups. Apoptotic cells
with brown nuclei were counted under a light microscope
in randomly chosen fields. The results showed that a signif-
icant increase in the apoptotic cells in combination group
Figure 2 Transduction of adenoviruses in LLC cells in vitro. A, adenoviral gene transduction efficiencies in murine LLC and human A549 cell
lines at indicated MOIs. B, HRP expression of LLC cells in various treatment groups was analyzed by western blot. C, IL-12 expression in the
supernatant of LLC cells infected with AdCMV(-), AdhTERTHRP and/or AdCMVmIL-12 was quantified using mIL-12p70 ELISA kit following the
manufacturer’s instructions. N.D., no detection. D, effects of transduction with different adenoviruses followed by IAA treatment in LLC cells in
vitro. Transduced cells were incubated with various concentrations of IAA for 5 days, and cell viability was determined by MTT assay. IC50 was
calculated as the concentration of drug which inhibited cell growth by 50%. Data were representative of three independent experiments. Each
point represented the means ± SEM and was expressed as percentage relative to drug-free cells.
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groups. The trend, combination > AdhTERTHRP >
AdCMVmIL-12 > AdCMV(-), implied that the apoptosis
inducing effects of combination strategy were more potent
than those induced by either AdCMVmIL-12 (P <0 . 0 0 1 ,
2.8-fold) or AdhTERTHRP (P < 0.001, 1.6-fold) alone in
LLC tumors. However, analysis of cell proliferation using
anti-Ki-67 antibody staining in tumors did not show any
significant differences between groups.
In vivo toxicity studies
To evaluate in vivo toxicity of various strategies with ade-
noviruses, biochemistry markers of liver and kidney in
sera and histological changes of key tissues were examined
from treated mice. The results showed that the liver and
kidney function was not impaired in each treatment group
(Figure 5A). Meanwhile, there were no obvious pathologi-
cal changes in heart, liver, spleen, lung and kidney of trea-
ted mice in comparison with animals without treatment
(Figure 5B-F). Neither serum markers nor histology dif-
fered between virus treatment groups versus normal con-
trol mice, suggesting that intratumoral administration
with AdhTERTHRP and/or AdCMVmIL-12 did not cause
detectable system toxicity.
Discussion
Gene therapy has been used extensively to cure a variety
of tumors in different experimental models [22]. How-
ever, the specificity of therapeutic gene expression was
unsatisfied [4]. To prevent the toxicity of suicide genes
in normal cells, tumor specific promoters including
hTERT promoter have been utilized to drive the specific
expression of ‘toxic’ genes in tumors of certain origins
[23-25]. hTERT is transcriptionally repressed in normal
human adult tissues but up-regulated in the majority of
human tumors from all tissues, which prompted the
investigations on the use of hTERT promoter to restrict
the expression of delivered genes to cancer cells and the
results were encouraging [4,26-28].
Suicide gene delivered by viral vectors was demonstrated
to be an effective approach for cancer treatment. Besides
direct killing effect on transduced cells, the bystander
effect of suicide gene therapy plays a crucial role in cancer
treatment due to it is impossible to transfer the suicide
Figure 3 In vivo evaluation of antitumor effect in a murine model of LLC. A, HRP expression in tumor tissues of various treatment groups
was analyzed by western blot. B, IL-12 expression in tumor tissue lysates of different treatment groups was quantified by ELISA. N.D., no
detection. C, tumor volumes were measured at the indicated time points after intratumoral injection with AdCMV(-), AdhTERTHRP, AdCMVmIL-12
alone or in combination. Each data point represented the mean tumor volume in that group. Error bars represented means ± SEM. B, long-term
survival of animals after treatment with different strategies. (n = 5 per group).
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the the host’s immune system plays an important role in
the bystander effect in vivo [29,30]. Thus, the improve-
ment of host’s immunity could enhance the bystander
effect of the suicide gene therapy. IL-12 is an important
macrophage-derived cytokine that can drive IFN-g pro-
duction, which exerted direct effects on the tumor or
recruited endogenous APCs (antigen present cells) and
effector T cells to the tumor site [31,32]. Local expression
of IL-12 (to maintain low serum concentrations to reduce
Figure 4 Effects of different treatments on tumor infiltration by immune cells, apoptosis and proliferation in LLC tumors. Treated mice
were sacrificed 24 hours after last IAA administration. Tumor sections were determined by immunohistochemical staining using specific antibodies
against CD4, CD8, Ki-67 and TUNEL assay. The positive cells were scored through light microscopy. After initial scanning under × 100 magnification,
positive stained cells in 10 filed under × 400 magnification were counted and the mean number of stained cells was averaged over 10 fields.
Table 1 Analyses of LLC tumor sections showing effects of different treatments on tumor infiltration by immune cells
and apoptosis
Treatment group Mean number/HPF ± SEM╪
Th cells (CD4) Cytolytic T cells (CD8) Apoptotic cells (TUNEL) Proliferating cells (Ki-67)
AdCMV(-) 14.8 ± 2.8 20.6 ± 4.9 2.1 ± 1.2 437.4 ± 39.7
AdhTERTHRP 67.2 ± 7.7 79.1 ± 9.4 25.8 ± 3.3 471.5 ± 51.7
AdCMVmIL-12 109.6 ± 11.0 143.1 ± 38.7 14.4 ± 1.7 409.6 ± 36.1
Combination 139.1 ± 17.6 177.2 ± 12.6 40.2 ± 4.4 463.3 ± 55.4
P* < 0.0001 < 0.0001 < 0.0001 > 0.05
╪After initial scanning under × 100 magnification, positive stained cells in 10 fields under × 400 (0.15 mm
2) magnification were counted and the mean number/
high-power field (HPF) was determined.
*Statistical analyses were conducted with one-way ANOVA for all the parameters. P values less than 0.05 were considered statistically significant.
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apy vectors [33]. Local concentration of IL-12 could not
only reduce toxicity but might be crucial for the establish-
ment of antitumoral immunity [34].
Therefore, strategies combined suicide gene with
immune-gene could enhance the antitumor effect than
either alone, which was demonstrated in several experi-
mental models [15,16,35,36]. In the present study, we
evaluated the therapeutic efficiency of target suicide
gene therapy mediated by hTERT promoter in combina-
tion with immuno-gene therapy in a murine model of
LLC both in vitro and in vivo.
Figure 5 In vivo toxicity studies. A, biochemistry markers in serum. The data were presented as means ± SEM of fiver animals per group. B-F,
representative images for histology of treated heart (B), liver (C), spleen (D), lung (E) and kidney (F) from combination group. (B-F), Magnification,
× 200; Scale bar, 50 μm. (B-F inserts), Magnification, × 400; Scale bar, 20 μm.
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(AdCMVmIL-12) were constructed based on adenovirus
due to its high transgene efficiency. However, the results
showed that murine LLC cells were relatively resistant to
adenovirus infection compared with human A549 cells
(Figure 2A), which was consistent with previous reports
[37]. The present study employed LLC cell line since it is
syngenic with the immunocompetent mouse model. The
expression of HRP protein was detected in AdhTERTHRP
alone and combination groups but not in AdCMV(-) or
AdCMVmIL-12 alone groups in vitro (Figure 2B) and
in vivo (Figure 3A). In the contrast, IL-12 was detected in
culture supernatant (Figure 2C) and tumor tissues (Figure
3B) in AdCMVmIL-12 and combination groups while not
in AdCMV(-) and AdhTERTHRP groups. The results
indicated that therapeutic genes were successfully deliv-
ered by adenovirus vectors and the tumor specific promo-
ter (hTERT) was efficient to drive target gene expression.
In addition, the HRP/IAA system was reported to be more
cytotoxic to tumor cells than the well-known HSV-tk/
GCV system, especially in the anoxia condition [11,12].
Strong cytotoxicity of HRP/IAA system in vitro was also
observed in the study with a dose dependent manner,
which further suggested the biological activity of HRP
coded by exogenous genes (Figure 2D).
For in vivo study, formation of tumor nodule and trans-
gene expression before IAA administration in the study
indicated that the present experimental system might
mimic some clinical situations and might be very suitable
for the purpose of assessing therapeutic effects. The com-
bination of AdhTERTHRP with AdCMVmIL-12 not only
showed significantly stronger tumor suppression effects
(Figure 3C), but also remarkably prolonged the survival
of animals (Figure 3D) compared with AdCMVmIL-12
alone, AdhTERTHRP alone and AdCMV(-).These find-
ings taken together with the fact that the tumor specific
hTERT promoter was sufficient to drive suicide gene
expression indicated that adenovirus-mediated HRP gene
therapy combined with cytokine IL-12 gene therapy
might be clinically therapeutic and useful for lung cancer.
We further investigated the possible mechanisms of
the enhanced antitumor effects by HRP/IAA and IL-12
combination gene therapy (Figure 4, Table 1). The
results indicated that the activities of HRP/IAA could
not only generate significantly cytotoxic activities locally,
but also potentially maximize tumor antigen presenta-
tion through its necrotic and apoptotic effects. The
addition of adenoviral vector-delivered locally active IL-
12 could potentially maximize the infiltration of specific
immune cells and cause them to be activated and
mature into active effectors, and thus effectively co-
operate with HRP/IAA gene therapy. Another major
focus of the present study was to evaluate whether sui-
cide gene therapy plus immuno-gene therapy had any
toxicity on the treated animals. The results showed that
there was no obviously systemic toxicity, as shown by
serum analysis for biochemical markers of liver and
kidney and the histological examination of hematoxylin
and eosin stained major organs (Figure 5). Taking all
these data into consideration, it appears that combina-
tion therapy of AdhTERTHRP/IAA and AdCMVmIL-12
had the best therapeutic effect in terms of tumor
growth, survival in the LLC tumor model and without
detectable system toxicity.
Conclusions
In summary, the concept of using targeted suicide gene
therapy in combination with immuno-gene therapy is
attractive for many malignancies. The present study
could be concluded that the combination therapy of
H R P / I A Aa n dI L - 1 2w e r ea b l et or e d u c et h et u m o r
growth and enhanced animal survival in the LLC
model. This combined system could provide a more
effective and less toxic therapy for cancer, although
further studies and clinical trials will be necessary in the
future.
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